Trichostatin A inhibits TGF-β1 induced in vitro chondrogenesis of hMSCs through Sp1 suppression

Jung-Pan Wang1, Ming-Hsuan Wen, Yi-Te Chen

  • 1Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.

Insights

Trichostatin A (TSA), a histone deacetylase inhibitor, was found to inhibit chondrogenesis in human mesenchymal stem cells (hMSCs). TSA blocks transforming growth factor-beta1 (TGF-β1)-induced chondrogenesis by suppressing Sp1 expression, a key factor in cartilage formation.

Area of Science:

  • Stem cell biology
  • Epigenetics
  • Chondrogenesis research

Background:

  • Histone deacetylase inhibitors (HDACi) like Trichostatin A (TSA) influence cell differentiation.
  • The impact of TSA on chondrogenesis, the process of cartilage formation, is not well understood.
  • Transforming growth factor-beta1 (TGF-β1) is a known inducer of chondrogenesis in human mesenchymal stem cells (hMSCs).

Purpose of the Study:

  • To investigate the effect of TSA on TGF-β1-induced chondrogenesis in hMSCs.
  • To elucidate the molecular mechanisms underlying TSA's influence on chondrogenesis.
  • To determine the role of Sp1 transcription factor in TSA's modulation of chondrogenesis.

Main Methods:

  • Pellet cultures of hMSCs were treated with TGF-β1 and TSA.
  • Chondrogenesis was assessed using quantitative reverse transcription/polymerase chain reaction (PCR) for chondrogenic genes (Sox9, Aggrecan, Col2A1), Alcian blue staining, and immunohistochemistry.
  • TGF-β1 signaling pathways and downstream targets were analyzed via western blot, including Smad 2/3 phosphorylation and Sp1 expression.

Main Results:

  • TGF-β1 significantly enhanced chondrogenic gene expression and protein synthesis.
  • TSA dose-dependently decreased chondrogenic gene expression and protein synthesis.
  • TSA inhibited TGF-β1-induced Sp1 expression but not Smad 2/3 activation, suggesting Sp1 is a key mediator.
  • Overexpression of Sp1 reversed the inhibitory effect of TSA on chondrogenesis.

Conclusions:

  • TSA inhibits TGF-β1-induced chondrogenesis in hMSCs by suppressing Sp1 expression.
  • Sp1 plays a critical role in mediating the chondrogenic effects of TGF-β1 and is a target for TSA's inhibitory action.
  • Sp1 may serve as a valuable target for future therapeutic strategies aimed at augmenting hMSC chondrogenesis, particularly for clinical applications.